Patents by Inventor Maurizio PROVENZANO

Maurizio PROVENZANO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-BK VIRUS ANTIBODY MOLECULES
    Publication number: 20240132575
    Abstract: Anti-BK virus antibody molecules or binding fragments thereof are disclosed. These Anti-BK virus antibody molecules or binding fragments can be used in the treatment or prevention of BK virus infection and/or BK virus associated disorder.
    Type: Application
    Filed: October 29, 2023
    Publication date: April 25, 2024
    Inventors: Marcel WEBER, Simone SCHMITT, Christoph ESSLINGER, Thomas SCHACHTNER, Uyen HUYNH-DO, Maurizio PROVENZANO
  • Anti-BK virus antibody molecules
    Patent number: 11919943
    Abstract: Anti-BK virus antibody molecules or binding fragments thereof are disclosed. These Anti-BK virus antibody molecules or binding fragments can be used in the treatment or prevention of BK virus infection and/or BK virus associated disorder.
    Type: Grant
    Filed: October 25, 2022
    Date of Patent: March 5, 2024
    Assignees: MEMO THERAPEUTICS AG, UNIVERSITÄT BERN, UNIVERSITÄT ZÜRICH
    Inventors: Marcel Weber, Simone Schmitt, Christoph Esslinger, Thomas Schachtner, Uyen Huynh-Do, Maurizio Provenzano
  • ANTI-BK VIRUS ANTIBODY MOLECULES
    Publication number: 20230192816
    Abstract: Anti-BK virus antibody molecules or binding fragments thereof are disclosed. These Anti-BK virus antibody molecules or binding fragments can be used in the treatment or prevention of BK virus infection and/or BK virus associated disorder.
    Type: Application
    Filed: October 25, 2022
    Publication date: June 22, 2023
    Inventors: Marcel WEBER, Simone SCHMITT, Christoph ESSLINGER, Thomas SCHACHTNER, Uyen HUYNH-DO, Maurizio PROVENZANO
  • INDOLEAMINE-2,3-DIOXYGENASE ASSAY FOR PROSTATE CANCER DIAGNOSIS AND PROGNOSIS
    Publication number: 20190241971
    Abstract: The invention relates to a method to predict a patient's risk of developing prostate cancer, or to distinguish indolent vs. aggressive cancers among patients suspected of bearing PCa and therefore selected for biopsy, and/or predict the risk of progression of prostate cancer in a patient having undergone prostate cancer treatment, particularly by radical prostatectomy, brachytherapy, and/or external beam radiation therapy, wherein said method comprises detecting/quantifying the level of indoleamine-2,3-dioxygenase (IDO) mRNA or protein in a urine sample obtained from said patient.
    Type: Application
    Filed: October 13, 2017
    Publication date: August 8, 2019
    Applicant: UNIVERSITAT ZURICH
    Inventors: Irina BANZOLA, Maurizio PROVENZANO